IGF1 Protein (AA 33-102)

Catalog No. ABIN2666831

This Recombinant IGF1 protein is expressed in Escherichia coli (E. coli).

Quick Overview for IGF1 Protein (AA 33-102) (ABIN2666831)

Target: IGF1 (Insulin-Like Growth Factor 1 (IGF1))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 33-102

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 3-15 ng/ml, corresponding to a specific activity of 0.6-3.3 x 105 units/mg, as determined by the dose dependent stimulation of MCF-7 cell proliferation.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: IGF1 (Insulin-Like Growth Factor 1 (IGF1))

Alternative Name: IGF-I

Background: Mouse IGF-I is a member of the IGF family that is comprised of three members: IGF-I, IGF-II, and insulin. IGF-I and IGF-II share approximately 50 % similarity with insulin at the amino acid level. Mouse IGF-I is synthesized as a 165 amino acid pre-pro-IGF-I, which includes the signal peptide, the mature protein, and the C-terminal E-peptide, the pro-IGFI possesses a proprotein convertase/furin cleavage site preceding the E-peptide. Pro-IGF-I is processed to the mature, active protein, and this procedure requires glucose regulating protein 94 (GRP94) that possesses chaperone activity towards IGF-I. Deletion of muscle GRP94 impairs muscle and body growth by inhibiting local production of IGF proteins. Seven binding proteins have been described (IGFBP-1 to 7). IGFBPs extend the half life and regulate the availability of IGF-I and IGF-II. It has been described that IGFBP3 is the main circulating binding protein for IGF's, in serum, approximately 75 % of circulating IGF-I and IGF-II bind to IGFBP3 and the co-carrier acid labile subunit (ALS). IGF-I binds to three receptors, and the binding to IGFIR promotes cell proliferation, survival, differentiation, and migration. IGF-I is a key factor for muscle growth and repair. Inactivation of IGF-RI in skeletal muscle leads to 10-30 % lower mass and delayed regeneration after injury.

Molecular Weight: The 71 amino acid recombinant protein has a predicted molecular mass of approximately 7.8 kDa. The DTT-reduced and non-reduced protein migrate at approximately 10 kDa and 11 kDa respectively by SDS-PAGE. The N-terminal amino acid is Met.

Pathways: RTK Signaling, Intracellular Steroid Hormone Receptor Signaling Pathway, Peptide Hormone Metabolism, Hormone Activity, Regulation of Intracellular Steroid Hormone Receptor Signaling, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Stem Cell Maintenance, Glycosaminoglycan Metabolic Process, Regulation of Carbohydrate Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Activated T Cell Proliferation, Positive Regulation of fat Cell Differentiation